Neurizon Therapeutics Limited has released a press release.
PharmAust Receives $672,250 R&D Tax Incentive Refund
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Story so far
Earlier from Neurizon Therapeutics
- Shortfall Placement Oversubscribed
- Phase I Monepantel Tablets Demonstrate High Safety
- PharmAust Raises $1.3m in Rights Issue
- MPL Tablets Demonstrate Positive Performance in Phase 1
- PharmAust Rights Issue Reaches Minimum Subscription
Later from Neurizon Therapeutics
- Phase I Canine Repeat Dose MPL Demonstrates High Performance
- Receipt of 25kg of GMP-Grade Monepantel from Elanco
- PharmAust Commences GMP Tablet Manufacture for Phase 2 Trial
- Epichem Final Loan Repayment Milestone for New Laboratory
- PharmAust receives ethics approval to begin Phase II Trial
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics